Genetic and Small Molecule Modifiers of Lysosomal Function
Funding Agency European Commission
Funding Programme Horizon 2020
Call/Topic H2020-MSCA-ITN-2015-ETN
Project reference 675007
Start date 2015.11.01
Duration 36 months
Total investment EUR 2 542 771 (EU contribution: EUR 2 542 771)
Project Coordinator Gonçalo Bernardes
Project Beneficiaries
- Instituto de Medicina Molecular João Lobo Antunes (iMM), Portugal;
- Faculdade de Farmácia da Universidade de Lisboa, Portugal;
- University College London, United Kingdom;
- Universidad de la Rioja, Spain;
- The Chancellor, Masters and Scholars of the University of Cambridge, United Kingdom;
- Institut Curie, France;
- Universitat Wien, Austria;
- Max-Planck-Gesellschaft zur Forderung der Wissenschaften EV, Germany.
Project Partners
- Pharmamar SA, Spain;
- Hovione SA, Portugal.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 675007.
Overview
ProteinConjugates is an inter- and multi-disciplinary network for the education of talented young scientists who will learn how to rationally design and construct the next generation of chemically-defined and innovative protein drug-conjugates for the targeted treatment of serious conditions such as cancer or rheumatoid arthritis.
A complementary interaction between academy and pharmaceutical industry is at the centre of such a network, which involves 8 academic groups and 2 leading European industrial partner organizations that will host secondments while providing training.
The combined expertise of the beneficiaries and industrial partners in synthesis of complex molecules, molecular dynamics, supramolecular self-assembly, site-selective chemical protein modification, protein/antibody engineering, cancer therapeutics and drug development together with the experience in project management and training of PhDs and Postdocs of the PIs, will create a multidisciplinary environment where 10 young researchers can foster their knowledge and skills while developing the most innovative ideas in the emerging fields of chemical site-selective protein modification and protein biotherapeutics. Exposure to the highly dynamic and multidisciplinary ProteinConjugates environment will contribute to the education of the next generation of leaders in the emerging field of protein biotherapeutics, a key area of research and drug development for Europe's competitiveness.